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Abstract
Prompted by findings that TGFβ stimulates thymine DNA glycosylase (TDG)
dependent rapid DNA demethylation and activation of the CDKN2B gene, I investigated the
global role of TDG and DNA demethylation in TGFβ signaling in HaCaT cells. Using dot
blot analysis, I show that TGFβ treatment increases the global levels of 5-formylcytosine, an
intermediate metabolite of active DNA demethylation. Characterization of genomic regions
that undergo DNA demethylation and recruitment of TDG indicate that they are both
frequent events, but only overlap at 11 genomic locations. I identified 440 TGFβ upregulated
genes, 40 of which were bound by TDG and 169 that exhibited DNA demethylation.
Distribution of the location of TDG peaks and DNA demethylation regions to the gene
promoter suggests that these events occur at distal elements. These results suggest that TDG
and DNA demethylation could be important factors involved in TGFβ’s regulation of gene
expression.
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Introduction

1.1

Regulation of gene expression
The proper control of gene expression in a cell-specific and temporal manner is a

requirement for the normal behaviour of all cells.

Specific sets of genes must be

dynamically regulated in response to various stimuli and during development.
Coordinating all of these changes to ensure they occur correctly involves several
regulatory steps.
1.1.1

Transcription factors and genomic regulatory elements
Transcriptional initiation is an important regulatory step that involves the

assembly of RNA polymerase II (RNAP) and transcription factors to the regulatory
elements of a gene locus (Maston et al., 2006). Typically, regulatory elements in a gene
locus include: The promoter, further subdivided into the core promoter, which surrounds
the transcription start site (TSS), and nearby proximal promoter elements; enhancers and
silencers, which act at variable distances from a TSS to activate or repress transcription,
respectively; and insulators, which block the transcriptionally activity of neighbouring
genes (Figure 1.1). Transcription regulators are bound at these elements and are classified
as: (1) general transcription factors, which include RNAP and auxiliary components that
assemble on the core promoter, (2) Sequence specific transcription factors that bind
directly to DNA at preferred sequences (motifs), and (3) coregulators that are recruited by
other transcription factors. Transcription factors can promote (activators) and/or suppress
(repressors) transcriptional activity through various mechanisms, including direct
interactions with the transcriptional machinery, modifying chromatin structure, and
recruitment of other transcription factors. Transcription factors and coregulators are
crucial for the regulation of their target genes. Through this regulation, transcriptional
regulators are important mediators of all biological processes and their expression
patterns can dictate cell type and tissue specificity.
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Figure 1.1. Regulatory elements at a gene locus. Transcription factor binding at the
following regulatory elements largely dictates the expression of a gene: The promoter,
which is the sequence surrounding the transcription start site, and enhancers, silencers,
and insulators which all act distally to the promoter to enhance or repress transcription.
Figure is adapted from Maston et al., (2006).
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1.1.2

Chromatin remodeling and histone modifications
In the cell nucleus, the fundamental repeating unit of chromatin is the nucleosome

which consists of DNA wrapped around an octamer of histone proteins consisting of 2
copies each of histones H2A, H2B, H3 and H4. Individual nucleosomes are connected by
a linker region consisting of DNA and histone H1 and are further packaged into various
levels of compaction. Chromatin acts as an intrinsic barrier to transcription, by preventing
access to RNAP and transcription factors to DNA. Therefore, to permit transcription an
important regulatory mechanism involves the modification and remodeling of chromatin
and histones. For example, ATP-dependent chromatin remodeling proteins control the
accessibility of DNA by sliding, ejecting, or restructuring nucleosomes (Narlikar et al.,
2013). A different mechanism involves modification of unstructured histone tails that
protrude away from the nucleosomal core. Specific residues on these tails are substrates
for enzymes that catalyze the addition or removal of post translational modifications,
such

as

phosphorylation,

acetylation,

methylation,

and

ubiquitination.

These

modifications can positively or negatively impact transcription by influencing chromatin
structure, or by functioning as docking sites for the recruitment of gene regulatory
proteins.
1.1.3

DNA methylation
DNA methylation is an important modification that is found primarily on the 5th

carbon of cytosine in a CpG dinucleotide, generating 5-methylcytosine (5mC). 5mC
formation is catalyzed by the DNA methyltransferase (DNMT) enzymes, which transfer a
methyl group from S-adenosyl methionine (SAM) onto cytosine. Members of the DNMT
family exhibit distinct functions in mammals: de novo methylation is established by
DNMT3A and DNMT3B, while methylation on the newly synthesized strand following
DNA replication is maintained by DNMT1, in association with UHRF1, which recruits it
to hemimethylated DNA (Bostick et al., 2007; Sharif et al., 2007). DNMT1 and
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DNMT3A/B are essential enzymes that are required for early development (Li et al.,
1992; Okano et al., 1999).
The distribution of CpGs and 5mC in the mammalian genome have distinct
patterns (Smith and Meissner, 2013): (1) The prevalence of a CpG dinucleotide in the
human genome occurs at much lower frequency than would be expected, (2) some CpGs
cluster into distinct regions called CpG islands (CGIs), and (3) non-CGI CpGs are
usually methylated, while CpGs in CGIs are typically unmethylated. Genomic CpG
depletion can be explained by the susceptibility for methylated cytosine to undergo
deamination to thymine, resulting in a reduction of non-CGI CpGs over time.
Cytosine methylation alters the biochemical properties of DNA, which can
negatively impact transcription depending on the genomic context. Strikingly,
approximately 60% of all gene promoters contain CGIs (Deaton and Bird, 2011). CGI
core promoters within transcriptionally active genes are often depleted of nucleosomes,
but are usually flanked by the H2A.Z histone variant and high levels of H3K4me3
(Deaton and Bird, 2011; Jones, 2012). Inactive CGI promoters are often nucleosome rich
and contain high levels of H3K27me3 and H3K4me3 marks (Jones, 2012; Schübeler,
2015). The majority of CGI within promoters are unmethylated regardless of gene
activity, which may, in part, be maintained by H3K4me3, which antagonizes DNMT
recruitment (Ooi et al., 2007; Schübeler, 2015). However, in imprinted genes, X
chromosome inactivation, and in heterochromatin containing repetitive elements and
transposons, DNA hypermethylation serves an important function in long-term silencing
(Jones, 2012). DNA methylation contributes to transcriptional silencing by interfering
with the binding of some transcription factors and/or by recruiting transcriptional
repressors that selectively bind 5mC.
Methylation is also important at genomic elements other than CGI promoters.
Although the genome-wide relationship between methylation of promoters not associated
with a CGI and expression is unclear, these promoters do exhibit cell-type specific
methylation (Jones, 2012). Enhancers often have variable DNA methylation levels and
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undergo genome-wide demethylation upon activation of transcription (Blattler et al.,
2014; Jones, 2012; Wiench et al., 2011). Furthermore, reporter assays have shown that
methylation of enhancer regions reduces transcriptional activity (Schmidl et al., 2009;
Wiench et al., 2011). Finally, gene bodies are commonly methylated in actively
transcribed genes (Jones, 2012). In this context, DNA methylation may have a role in
regulating splicing (Lev Maor et al., 2015).
Methylation patterns are dramatically altered in cancer. Cancer cells often exhibit
genome-wide hypomethylation that primarily occurs in repetitive regions, and contributes
to genomic instability (Robertson, 2005). In contrast, DNA hypermethylation of CGI
promoters in tumour suppressor genes, such as MGMT, RB1, and BRCA1, is associated
with transcriptional silencing (Esteller, 2007). The molecular basis for aberrant
methylation in cancer is not completely understood.
1.2

DNA demethylation
Removal of the 5mC mark (DNA demethylation) can occur through two general

mechanisms: Passive demethylation, which involves the loss of 5mC during successive
rounds of replication in the absence of functional DNA methylation maintenance
machinery, and active DNA demethylation, an enzymatic process that removes or
modifies the methyl group from 5mC. The importance of these mechanisms were initially
recognized during embryonic development. Shortly after fertilization, the maternal
genome undergoes passive DNA demethylation that is dependent on DNA replication. In
contrast, the paternal genome is rapidly demethylated prior to the first cell division
suggesting that the process is active (Smith and Meissner, 2013).
1.2.1

TET mediated DNA demethylation
The discovery of a family of enzymes that can modify 5mC into 5-

hydroxymethylcytosine (5hmC) has greatly advanced our understanding of DNA
demethylation mechanisms. This discovery was motivated in large part, by work on the
biosynthesis of Base J in Trypanosoma brucei (Borst and Sabatini, 2008). Production of
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Base J involves oxidation of thymine to 5-hydroxymethyluracil (5hmU) by J binding
protein 1 (JBP1) and JBP2, members of the Fe(II)/α-ketoglutarate (α-KG)-dependent
oxygenase family of enzymes. Bioinformatic analyses identified mammalian orthologues
of JBP1 and JBP2 that belong to the ten-eleven translocation (TET) family (Tahiliani et
al., 2009). The same study demonstrated that TET1 catalyzes oxidization of the methyl
group of 5mC, generating 5hmC. It was later determined that 5hmC can be iteratively
oxidized into 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) by the TET enzymes
(Ito et al., 2011). 5hmC, 5fC, 5caC, collectively called methylcytosine oxidized
metabolites, can accumulate in some tissues and can be diluted through successive DNA
replications, as is the case for 5hmC during preimplantation development (Inoue and
Zhang, 2011; Wu and Zhang, 2014). Alternatively, in vitro assays show that 5fC and
5caC are specifically recognized and excised by thymine DNA glycosylase (TDG) (He et
al., 2011; Maiti and Drohat, 2011). TDG excision of 5fC/5caC generates an abasic site
that is processed by the base excision repair (BER) pathway, which replaces the abasic
site with cytosine (Figure 1.2). This mechanism is further supported by studies showing
that 5fC/5caC accumulate in TDG depleted mESCs (Shen et al., 2013).
TET1 expression is found primarily in embryonic stem cells, and is
downregulated following differentiation. In contrast, TET2 and TET3 are ubiquitously
expressed in adult tissues. TET mediated oxidation involves a base flipping mechanism,
which positions the cytosine derivative in the catalytic site (Shen et al., 2014). The
reaction involves molecular oxygen, α-KG, and Fe(II) to generate a Fe(IV)-oxo
intermediate that acts on 5mC, 5hmC, or 5fC to generate the subsequent metabolite.
Common to all three TET proteins is the catalytic domain at the C-terminal end (Shen et
al., 2014). The core of the catalytic domain is a double stranded β-helix (DSBH) fold
composed of eight anti-parallel β-strands. The amino –terminus of TET1 and TET3, but
not TET2, contain a CXXC (cysteine-X-X-cysteine) domain (Shen et al., 2014). In vitro
binding assays have shown that the TET1 and TET3 CXXC domains bind preferentially
to CG rich DNA (Xu et al., 2012; Zhang et al., 2010), which suggests that this domain
may be important for targeting TET1/3 to specific sequences. All three TET proteins are
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O-GlcNAcylated, which promotes nuclear export of TET3 (Bauer et al., 2015; Chen et
al., 2013; Shi et al., 2013; Zhang et al., 2014). Mass spectrometry analysis identified that
TETs can also be phosphorylated, which is reduced by increased O- GlcNAcylation,
suggesting that there is an interplay between these modifications (Bauer et al., 2015).
A fusion of the amino terminal region of TET1 with the histone methyltransferase
mixed lineage leukemia (MLL) has been identified in several cases of acute myeloid
leukemia (AML) (Shen et al., 2014). Mutation of TET2 is highly prevalent in chronic
myelomonocytic leukemia (CML), AML, and myelodysplastic syndromes (MDS), and
deletion of TET2 in mice leads to the development of myeloid malignancies (Huang and
Rao, 2014; Li et al., 2011). Also, global levels of 5hmC are reduced in a number of
different cancers (Lian et al., 2012; Yang et al., 2012). Thus, TET proteins are believed to
function as tumour suppressors (Shen et al., 2014).
1.2.2

Methylcytosine oxidized metabolites are potential functional epigenetic
marks
In addition to functioning as metabolic intermediates, genome-wide studies

indicate that 5mC derivatives can accumulate at some regions of the genome suggesting
that they represent epigenetic marks that are important for transcription. In embryonic
stem cells (ESCs), 5hmC is enriched at active distal enhancers, gene bodies, and in the
promoters of low to medium expressing genes, while 5fC/5caC are enriched at enhancers
containing both activating and repressive histone modifications (poised enhancers) (Song
and He, 2013; Song et al., 2013a; Wu and Zhang, 2014; Yu et al., 2012). Interestingly, in
the absence of TDG, 5fC/5caC accumulate at active distal enhancers in ESCs (Shen et al.,
2013; Song et al., 2013a). This accumulation at regulatory elements is believed to occur
through recruitment of TETs and TDG by transcription factors to these particular regions
(Song and He, 2013; Wu and Zhang, 2014).
Mass-spectrometry-based proteomic approaches have identified specific readers
for each 5mC modification in mESCs and adult mouse brain tissue (Iurlaro et al., 2013;
Spruijt et al., 2013). Importantly, each cytosine modification recruits a distinct set of
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proteins with known functions in transcriptional regulation and active demethylation. In
vitro studies have shown that RNAP elongation efficiency is reduced when a DNA
template contains 5fC or 5caC, but unaffected when the template contains cytosine, 5mC,
or 5hmC (Kellinger et al., 2012). This was also observed in 293T cells (You et al., 2014).
Collectively, these studies indicate that the oxidized metabolites have important
regulatory functions in gene expression.
1.2.3

AID/APOBEC mediated DNA demethylation
An alternative pathway resulting in DNA demethylation has also been proposed

involving deamination (removal of an amine group) by Activation-Induced Deaminase
(AID)/apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like (APOBEC)
enzymes (figure 1.2). AID was previously known to be involved in antibody diversity by
mediating the error prone process of deamination of cytosine to uracil followed by repair
of the U:G mismatch by TDG/BER pathway or the mismatch repair pathway (Bhutani et
al., 2011). An in vitro study demonstrated that AID/APOBEC can act on 5mC and
deaminate this DNA base to thymine (Morgan et al., 2004). Overexpression of AID and
the glycosylase methyl-CpG binding domain 4 (MBD4) in zebrafish caused
demethylation of the genome and an injected methylated DNA construct (Rai et al.,
2008). AID/APOBEC mediated demethylation has been identified in primordial germ
cells, pluripotency reprogramming, and the epithelial-mesenchymal transition (EMT)
(Bhutani et al., 2010; Munoz et al., 2013; Popp et al., 2010). Also, AID/APOBEC
overexpression leads to demethylation of a co-transfected 5hmC-containing reporter
plasmid and increased levels of 5-hydroxymethyluracil (5hmU), a deaminated product of
5hmC, in HEK293 cells (Guo et al., 2011). Collectively, these studies have demonstrated
a role for AID in DNA demethylation by meditating deamination of 5mC and 5hmC.
However, since these discoveries, the feasibility of these deamination mechanisms has
been put into question by an in vitro study demonstrating that the enzymes greatly favour
cytosine as their substrate over modified cytosine (Nabel et al., 2012; Wu and Zhang,
2014).
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Figure 1.2. DNA demethylation mechanisms. In passive DNA demethylation, the loss
of 5mC or its metabolites occurs through successive rounds of DNA replication in the
absence of functional DNA methylation maintenance machinery. Active DNA
demethylation can occur through: (1) TET1/2/3 iterative oxidization of 5mC to 5hmC,
5fC, and 5caC, followed by TDG excision of 5fC and 5caC and replacement of the abasic
site with cytosine via the BER pathway, or (2) AID/APOBEC mediated deamination of
5mC to thymine, or 5hmC to 5hmU, followed by TDG excision and BER processing.
Figure is from (Bhutani et al., 2011).
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1.2.4

TDG
TDG is a member of the uracil DNA glycosylase (UDG) family of enzymes and

was originally identified as a component of the BER pathway involved in DNA repair.
TDG contains a catalytic glycosylase domain that recognizes and excises thymine from a
G:T lesion and also uracil from a G:U mismatch generating an abasic site (Xu et al.,
2015). Because TDG is tightly bound to the abasic site, the dissociation of TDG from the
abasic site is the rate-limiting step of the reaction (Sjolund et al., 2013).
Apurinic/apyrimidinic endonuclease (APE1) binds to TDG and promotes its dissociation
from the abasic site (Waters et al., 1999). Sumoylation of TDG also promotes its
dissociation (Sjolund et al., 2013). After TDG is released, APE1 cleaves the DNA
backbone generating a single nucleotide gap that is filled in by DNA polymerase β (pol
β) and sealed by DNA ligase (Sjolund et al., 2013; Xu et al., 2015).
As previously mentioned, TDG can recognize and excise 5fC, 5caC and the G:T
mispair generated by deamination of 5mC. In addition, TDG can excise 5hmU
(Cortellino et al., 2011). Interestingly, TDG interacts with DNMT3A and an in vitro
assay showed that TDG represses the methyltransferase activity of DNMT3A (Li et al.,
2007). TDG also associates with AID and all three TET proteins (Cortellino et al., 2011;
Müller et al., 2014). Thus, TDG has a central role in DNA demethylation.
TDG has an important role in gene expression by acting as an essential
transcriptional coactivator. TDG directly associates with cAMP response elementbinding protein (CBP) and enhances CBP transcriptional activity (Tini et al., 2002). TDG
has been shown to associate with numerous transcriptional regulators and nuclear
receptors, including the estrogen receptor alpha (ERα), retinoic acid receptor alpha
(RARα), steroid receptor coactivator-1 (SRC1), and transcription factor 4 (TCF4) (Chen
et al., 2003; Jia et al., 2014; Léger et al., 2014; Lucey et al., 2005). It is currently unclear
if TDG’s transcriptional coactivator function is coupled to its role in DNA demethylation.
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TDG null embryos die around E12.5 suggesting that it plays an important role in
development (Cortázar et al., 2011; Cortellino et al., 2011). This makes TDG unique
from other UDG family members (uracil DNA glycosylase (UNG), MBD4, single-strandselective monofunctional uracil-DNA glycosylase 1 (SMUG1)), which are all dispensable
for embryonic development (Wu and Zhang, 2014). Expression of developmental genes
was impaired in TDG null mice, attributed to histone modifications changes, altered
recruitment of CBP and MLL, and gene promoter hypermethylation (Cortázar et al.,
2011; Cortellino et al., 2011). In contrast, DNA repair was deemed unaffected. These
findings demonstrated a pivotal role for TDG in maintaining epigenetic stability during
development.
1.3

The TGFβ signaling pathway
The combination of transcription factors, coregulators, histone modifications, and

DNA methylation play a crucial role in controlling gene expression. Many of these
factors can be controlled through signal transduction pathways to elicit a change in gene
expression. One important example is the transforming growth factor beta (TGFβ)
pathway.
1.3.1

TGFβ signaling system
TGFβ is a cytokine that drives cell-type specific gene expression changes to

regulate cell proliferation, apoptosis, development, and homeostasis. The signaling
pathway is composed of different ligand isoforms, membrane bound receptors,
transcription factors, coregulators, and chromatin modifiers. In this thesis, the focus is on
the TGFβ1 ligand. The canonical TGFβ activated ligand binds to TGFβ receptor
complexes containing serine/threonine kinases, which induces receptor transphosphorylation and kinase activation. Next, the TGFβ type 1 receptor (TβR1)
phosphorylates SMA- and MAD-related 2 (SMAD2) and SMAD3 (receptor activated
SMADS, R-SMADs), promoting oligomerization of R-SMADs with SMAD4. Upon
complex formation, R-SMADs/SMAD4 are translocated into the nucleus, where they
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bind directly to DNA, and associate with many other transcription regulators to regulate
the expression of hundreds of genes.
However, that does not depict the whole story and additional features complicate
TGFβ signaling. A negative feedback loop is established by genes that are induced by
TGFβ and inhibit the signaling pathway. For example, SMAD7 expression is induced by
TGFβ and competitively inhibits phosphorylation of R-SMADs, recruits phosphatases to
inactivate the receptors, and promotes ubiquitination and subsequent degradation of
TβR1 (Pardali and Moustakas, 2007). Also, different combinations of the signal
transduction components and transcriptional regulators, as well as the epigenetic
landscape comprise the ‘contextual determinants of TGFβ action’, which largely dictates
how a cell will respond to TGFβ (Massagué, 2012). Finally, TGFβ can activate other
signaling pathways (e.g. MAPKs, PI3K) and other signaling pathways can activate the
SMADs.
1.3.2

TGFβ transcriptional mechanisms and responses
SMADs are an example of transcription factors that can either activate or repress

transcription. This is achieved by associating with a number of different DNA binding
transcription factors and coregulators. Commonly associated transcription factors include
specificity protein 1 (SP1), CCAAT/enhancer binding protein (C/EBPβ), nuclear factorkappaB (NF-κB) and members of the forkhead box (FOX), runt-related transcription
factor (RUNX), and activating protein 1 (AP1) families (Massagué et al., 2005; Ross and
Hill, 2008). Transcriptional coregulators involved include p300, CBP, and p300/CBP
associated factor (P/CAF), p107, and various histone deacetylases (HDACs) (Massagué
et al., 2005). Brahma-related gene-1 (BRG1), an ATP dependent chromosome
remodelling complex, directly interacts with SMAD2 and SMAD3 and plays an
important role in TGFβ transcriptional activation and repression (Xi et al., 2008). Thus, a
multitude of transcription factors, coregulators and chromatin modifiers are involved in
TGFβ’s gene expression program.
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TGFβ orchestrates a cytostatic response in epithelial, endothelial, and
hematopoietic cells (Pardali and Moustakas, 2007). This response results in arrest in the
cell cycle at G1 and is achieved by multiple mechanisms. A key step is the TGFβdependent recruitment of SMAD3, p107, and E2F4 to the c-MYC promoter,
downregulating this mitogenic transcription factor (Chen et al., 2002). TGFβ also induces
SMAD mediated transcriptional repression of inhibitor of differentiation family members
(ID1/2/3), which is necessary for TGFβ growth arrest (Kang et al., 2003; Pardali and
Moustakas, 2007). Transcriptional induction of cyclin dependent kinase inhibitors (CKIs)
is also a key mechanism used by TGFβ to arrest the cell cycle. In a complex with SP1,
the SMADs bind to the promoters of cyclin dependent kinase inhibitor 2B (CDKN2B,
also called p15) and cyclin dependent kinase inhibitor 1A (CDKN1A, also called p21) to
dramatically upregulate their transcription (Feng et al., 2000; Pardali et al., 2000).
In EMT, epithelial cells lose cell-cell junctions and change polarity, while at the
same time reorganizing the cytoskeleton, acquiring motile and invasive capabilities, and
ultimately, adopt a mesenchymal phenotype (Lamouille et al., 2014). TGFβ induces EMT
in multiple cell types primarily by upregulating several transcription factors involved in
promoting EMT. For example, TGFβ treatment upregulates snail zinc finger 1 (SNAIL),
snail zing finger 2 (SLUG), zinc finger E-box binding homeobox 1 and 2 (ZEB1/2)
transcription factors, and stimulates them to localize to the epithelial cadherin (ECadherin or ECAD) promoter and repress ECAD transcription via recruitment of
repressive complexes (Xu et al., 2009). The downregulation of ECAD, an adherens
junction protein, is a hallmark event in EMT. Many additional transcriptional changes
occur in TGFβ induced EMT that ultimately result in the downregulation of epithelial
markers and upregulation of mesenchymal markers (Xu et al., 2009).
In addition to growth arrest and EMT, TGFβ can also promote apoptosis, regulate
angiogenesis, and modulate immune cells (Tian et al., 2011). Thus, TGFβ has many
tumour promoting and tumour suppressive effects. Importantly, cancer cells often find a
way to inactivate the tumour suppressive axis, while still enabling the tumour promoting
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functions of TGFβ (Kubiczkova et al., 2012). An understanding of the mechanisms
behind this switch is an important area of research in order to properly target TGFβ and
its paradoxical functions in cancer.
1.4

Rationale & hypothesis
Previous work in my lab showed that the CDKN2B promoter is rapidly

demethylated in response to TGFβ treatment in HaCaT cells (Thillainadesan et al., 2012).
TDG, AID, and BER components were recruited within 90 minutes of TGFβ treatment
and TDG was required for the TGFβ-dependent demethylation and induction of
CDKN2B. In addition, 5hmC accumulated on the CDKN2B promoter in TDG depleted
cells. This work presented a mechanism whereby TGFβ treatment stimulates oxidation
and/or deamination of 5mC at the CDKN2B promoter in conjunction with TDG
recruitment and processing of the 5mC metabolites. Dot blot analysis also showed that
global 5mC levels are decreased by TGFβ in a TDG-dependent manner (Thillainadesan et
al., 2012). This finding prompted the hypothesis for my project: TDG dependent DNA
demethylation is a global mechanism used to regulate TGFβ induced gene
expression. The objectives to test this hypothesis were as follows:
1)

Assess global TGFβ induced changes in the oxidized methylcytosine
metabolites.

2)

Characterize global TGFβ dependent TDG binding and DNA
demethylation and their relationship with gene expression.

3)

Determine if TDG is essential for TGFβ-dependent growth arrest and
EMT induction.
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Figure 1.3. The canonical TGFβ signaling pathway. TGFβ ligand binding to its
receptors induces activation of the receptor’s kinase domain. SMAD2/3 are then
phosphorylated by the activated TGFβ receptor, promoting oligomerization with SMAD4
and entry into the nucleus. In the nucleus, SMADS associate with numerous
transcriptional regulators to activate or repress transcription of hundreds of genes. A
negative feedback loop is established by induction of genes (e.g. SMAD7, Smurfs) that
inhibit SMAD2/3 phosphorylation or target components of the pathway for degradation.
Figure is adapted from (Pardali and Moustakas, 2007).
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2

Materials & Methods

2.1

Cell culture, TGFβ treatments, and transfections
HaCaT cells and mouse embryonic fibroblasts (MEFs) were cultured in

Dulbecco’s modified Eagle medium (DMEM), supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (all from Wisent). For EMT experiments, media
for HaCaT cells was changed to low calcium DMEM for at least 48 hours prior to
treatment. All cells were maintained in a 37˚C incubator with 5% CO2. For TGFβ (R&D,
240-B) treatments, HaCaT cells were grown to approximately 60% confluency and serum
starved (0% FBS) for 24 hours. Media was then replaced with DMEM containing 10%
FBS and 5ng/mL TGFβ or vehicle (4 mM HCl containing 0.1% human BSA). For
transfections, HaCaT cells were seeded overnight and transfected using Lipofectamine
2000 and control siRNA (Dharmacon, D-001210-03-50) or siTDG (Dharmacon, M040665-01). To excise TDG in Tdgflox/flox;UB-Cre/ERT2+ MEFs, cells were treated with
100 nM tamoxifen for 48 hours.
2.2

Dot blot analysis of 5mC, 5hmC, and 5fC
Genomic DNA was isolated from HaCaT cells using the GeneElute Mammalian

Genomic DNA miniprep kit (Sigma, G1N70). DNA samples were denatured at 100˚C for
10 minutes in 0.1 M sodium hydroxide, crunched on ice for 5 minutes, and then
neutralized with 1/10th the volume of cold 6.6M ammonium acetate. DNA was then
applied to a positively charged nylon membrane (Hybond N+, RPN2020B) using a
filtration manifold (Schleicher & Schuell). The membrane was then baked in an 80˚C
oven under vacuum for 30 minutes, incubated in blocking buffer (5% milk, PBS, 0.1%
Tween-20) for one hour, and incubated with the following antibodies overnight at 4˚C in
blocking buffer: anti-5mC (1:2000, Millipore, 33D3), anti-5hmC (1:1000, Active Motif,
39769), and anti-5fC (1:1000, Active Motif, 61223). The membrane was then washed
several times, incubated with secondary antibodies (1:10,000, anti-Mouse (GE, NA931V)
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or anti-Rabbit (GE, NA934V) for 1 hour, and washed again, all in blocking buffer. The
chemiluminescent signal was detected using Enhanced chemiluminescence (ECL)
(Millipore, WBLUF0100) and a chemidoc MP system. After imaging, the membrane was
incubated in 0.02% methylene blue with 0.3M sodium acetate, followed by destaining in
water.
2.3

ChIP-Seq, MeDIP-Seq, and RNA-Seq
The DNA for the ChIP-Seq and MeDIP-Seq experiments were prepared as

described in Thillainadesan, et al. (2012), except that lysates were pre-cleared by an IgG
antibody to reduce non-specific binding. HaCaT cells were serum starved and treated
with TGFβ for 90 minutes for the ChIP and 3 hours for the MeDIP. Library construction,
Illumina HiSeq sequencing (75 base pair paired-end reads), and sequence alignment of
the ChIP and MeDIP samples (untreated and treated) was conducted at the Michael Smith
Genome Sciences Centre at the British Columbia Cancer Agency (Vancouver, BC). I
conducted validations of the ChIP-Seq as described in Thillainadesan, et al., (2012),
except that a commercial antibody for TDG (Thermo Scientific, PA5-29140) was used
and a 5 minute incubation with 0.125 M glycine was included after formaldehyde crosslinking. Primer sequences for ChIP-qPCR are listed in 2.9.
Cell treatments and RNA isolation for the RNA-Seq experiment were conducted
by Majdina Isovic. HaCaT cells were serum starved and then treated with TGFβ, or
vehicle, for 3 and 16 hours. RNA was collected using RNeasy kit (Qiagen, 74104). RNA
integrity was assessed by an Agilent 2100 Bioanalyzer at the London Regional Genomics
Centre at Robarts Research Institute (London, ON). Library construction and sequencing
using Illumina HiSeq platform (101 base pair paired-end reads) was conducted at The
Centre for Applied Genomics at The Hospital for Sick Children (Toronto, ON). I
conducted RNA-Seq validations as described above. cDNA was reversed transcribed
using a reverse transcription using High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, 4368814) followed by SYBR-green based qPCR (Applied
Biosystems, 4367659). Primer sequences are listed in 2.9.
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2.4

ChIP-Seq data analysis
Bioinformatic analysis of aligned reads (hg19) was completed using Partek

Genomic Suite 6.6 (PGS). Only reads that were of sufficient quality and aligned
unambiguously were used. To detect ChIP-Seq peaks, the genome was divided into 200
base pair windows and midpoints of peaks within a window were counted and an
empirical distribution of window counts was created. PGS uses a zero truncated binomial
model to fit the distribution and calculate a false discovery rate (FDR). 29,191 peaks with
a FDR less than 0.01 were scored. To identify TGFβ dependent TDG recruitment, peaks
containing a greater than 2 fold scaled fold change between treatment and control were
used in downstream analysis (3364 peaks). Scaled fold change compares the intensity of
signal of the TGFβ sample to the control sample and is scaled by a ratio of the number of
total alignments of each sample on a per chromosome basis. PGS, which uses the Gibbs
motif sampler, was used for de novo motif analysis using the default parameters. Known
motif analysis was conducted using the JASPAR database. CpG islands were downloaded
from the ENCODE database. RefSeq (2014-10-17) was used to annotate location of a
peak to a genomic feature, defining the promoter as -50 kbp to +3kbp or -5kbp to +3kbp,
as indicated. Gene Ontology analysis was conducted as described in 2.6.
2.5

MeDIP-Seq data analysis
Bioinformatic analysis of aligned reads (hg19) was completed using PGS. Only

reads that were of sufficient quality and aligned unambiguously were used. Differentially
methylated regions (DMRs) were detected using 200 base pair windows and FDR of
0.001. To identify TGFβ dependent regions with a methylation loss, only regions
containing a greater than 2 fold methylation loss after treatment were used in downstream
analysis (8230 peaks). All other analysis was conducted similarly to the ChIP-Seq.
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2.6

RNA-Seq data analysis
RNA-Seq raw reads were filtered and aligned to hg19 using TopHat2 (2.0.11) and

summarized to RefSeq (2014-10-17) transcripts using default parameters. Reads Per
Kilobase of exon model per Million mapped reads (RPKM) was used to normalize
between samples and values were compared between TGFβ and control to identify genes
that were up or down regulated at each time point. Gene Ontology (GO) analysis was
conducted in PGS using the fisher’s exact test and excluded functional groups containing
less than 10 genes.
2.7

Protein extraction, Western blot, antibodies
Cells were washed twice in phosphate-buffered saline (PBS), harvested and lysed

in RIPA lysis buffer consisting of 0.15M NaCl, 1% NP-40, 0.5% sodium deoxycholate,
0.1% SDS, and 50 mM tris (pH 8), and protease inhibitor cocktail. The lysates were
incubated on ice for 20 min and then centrifuged for 15 min at 15,000 rpm at 4˚C to
remove insoluble cellular material. The supernatant was retained and protein
concentrations were determined using Bradford assay. Samples were normalized for
protein content and were separated by SDS-PAGE, transferred to PVDF membrane and
incubated overnight in blocking buffer (see 2.2). The appropriate antibodies were then
diluted in blocking buffer and the membrane was probed for 2 hr at room temperature
with rocking, followed by addition of the appropriate secondary antibody (1:10 000
dilution) for 1 hr. Proteins were detected using ECL according to the manufacturers
recommendations (Millipore, WBLUF0100). Blots were quantified using Image Lab
Software (Bio Rad, #1709690). The following antibodies were used: TDG (Thermo
Scientific, PA5-29140), TDG (gift from Marc Tini, used for detection of mouse TDG
only), Vinculin (Sigma, V9264), p15 (Santa Cruz, C-20), E-Cadherin (BD Biosceinces,
610181), and N-Cadherin (BD Biosciences, 610920).
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2.8

Growth curve
72 hours post-transfection, HaCaT cells were seeded at 125, 000 cells/well in a 6

well dish and treated with TGFβ or vehicle four hours later. Cells were trypsinized every
24 hours post treatment and a cell concentration was determined using a hemocytometer.
MEFS were treated for 48 hours with 100 nM tamoxifen to induce excision of TDG.
Cells were then harvested and seeded overnight in a 6 well dish. Cell number was
counted the next day and used as the number of cells at time 0. Cells were then treated
with vehicle or TGFβ and cell concentration was counted every 24 hours post-treatment
using a MOXI Z Mini Automated Cell Counter (ORFLO, MXZ001).
2.9

Primer sequences
RNA analysis

Gene

Forward 5’-3’

Reverse 5’-3’

GAPDH

GTTTCTATAAATTGAGCCCGCAG

CGACCAAATCCGTTGACTCC

TDG

CAAATGGGCTAATTGAGAGCCGT

CAAACTAGGTTCTACTTGTGAC

EREG

ACAGCTTTAGTTCAGACAGAAGAC

CATCGGACACCAGTATAACCC

SIRPA

CGGAACATCTATATTGTGGTGGG

TCATGCAACCTTGTAGAGAAGTG

IFIT2

AGCATTTATTGGTGGCAGAAGAG

TATTGTTCTCACTCATGGTTGCA

PDZK1

CATCTCCAGAAATGACCTCCA

ATTCCCACTCTTTATGACCA

PIK3IP1

CCAGAACAGCATAACAAGGG

CAGAAACAGCCTCCAGATCC
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ChIP-qPCR analysis
Gene

Forward 5’-3’

Reverse 5’-3’

MMP9

CCTGATCAACATGGAGAAACCC

AAGAGTTTCCGCTGTTGTTCC

COL4A2

GCATGGGAAGAGGAAGAAGAC

CTCGTTTCCCTCCATTGTTCTC

AK8

GCAATTCCTCCAACAATCAATGTG

GGGTTAGAAGTCAGCAGGTC

HAS2

AGACTTCCTACCTTTATCCAAGAG

GCATTATTAGGACTGATAGCGA
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3

Results

3.1

TGFβ-dependent changes in global 5mC oxidized metabolites
Previous studies have shown that a 90 minute TGFβ treatment decreases global

levels of 5mC in HaCaT cells (Thillainadesan et al., 2012). Importantly, the 5mC
decrease was TDG dependent, raising the possibility that this decrease involves a TDG
mediated active DNA demethylation pathway. To assess whether the TET/TDG active
demethylation pathway is regulated by TGFβ, I used a dot blot assay to monitor changes
in 5mC oxidized metabolites. The dot blot assay involves immobilization of DNA onto a
membrane, followed by a traditional western blot procedure using a primary antibody
that is specific for 5mC, 5hmC, or 5fC. Preliminary experiments were necessary in order
to validate the consistency of the assay by analyzing signal intensity of serially diluted
DNA samples using 5mC, 5hmC, and 5fC antibodies (Figure 3.1A). Following
validation, I confirmed that global 5mC decrease occurs after a 3 hour TGFβ treatment in
HaCaT cells (Figure 3.1B, left). Next, I used this time point to assess TGFβ-dependent
global changes in 5hmC and 5fC. TGFβ caused a slight but consistent global decrease in
5hmC levels (Figure 3.1B, middle). Interestingly, while both 5mC and 5hmC are
decreased by TGFβ, a 3-fold global increase in 5fC was also observed (Figure 3.1B,
right). Collectively, these results suggest that DNA demethylation mechanisms are
regulated globally in response to TGFβ signaling and shows for the first time a signal
directed change in 5fC.
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Figure 3.1. TGFβ causes rapid global changes of oxidized 5mC metabolites in
HaCaT cells. A) Validation of the dot blot assay. Serial dilutions of DNA were applied
to a nylon membrane in duplicate and probed with the indicated antibodies. B) Dot blot
analysis of genomic DNA isolated from HaCaT cells treated with or without TGFβ
(5ng/mL) for 3 hours. Methylene Blue is used as a control for DNA loading. Blots are
representative of three independent experiments.
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3.2

Genome-wide Analysis of TDG recruitment and DNA demethylation
To identify the genomic locations where active demethylation occurs as well as

understand its importance to TGFβ signaling, an approach was taken using ChIP-Seq,
MeDIP-Seq, and RNA-Seq methodologies in TGFβ treated HaCaT cells (Figure 3.2).
The use of HaCaT cells for this study is warranted because they are a non-tumourigenic
cell line that is TGFβ responsive (Boukamp et al., 1988), which allows for investigation
of the signaling network under a more ‘normal’ physiology as compared to cancer cells.
Additionally, HaCaT cells are a well validated model system previously used to
characterize TGFβ-dependent gene regulation (Levy and Hill, 2005; Xi et al., 2008;
Zavadil et al., 2001).
Genomic locations for TDG were identified using ChIP-Seq in control and TGFβ
treated HaCaT cells (90 min). This time point was chosen based on previous experiments
by my lab demonstrating maximal recruitment of TDG at the CDKN2B promoter
following a 90 minute TGFβ treatment (Thillainadesan et al., 2012). Approximately 200
million reads were obtained for each sample and after filtering, the remaining reads were
aligned to the human genome. Peaks were detected using an FDR of 0.01 and a window
size of 200 bps. A 2-fold increase in signal intensity between the TGFβ sample and the
untreated was used as the cutoff. Based on this analysis, 3364 TGFβ dependent peaks
were identified (Figure 3.3A).
Remarkably, the CDKN2B locus, located on chromosome 9, exhibited a 566 fold
increase in TDG binding (Figure 3.3C). This peak had the greatest fold change between
TGFβ-treated and untreated cells, with the next highest fold change being 23. Analysis of
the distribution of TDG binding along individual chromosomes indicated that TDG
recruitment is not dependent on chromosome size, suggesting that the binding is not
random (Figure 3.3B). It also revealed a strong preference for TDG recruitment on
chromosome 9. To investigate if TDG recruitment is occurring at CpG islands, a mapped
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list of CpG islands was downloaded from the ENCODE database. Surprisingly, TDG
recruitment overlaps with only 18 CpG islands (0.56% of TDG recruited sites, figure
3.3D). The most abundant de novo motif identified within TDG binding sites is a purinerich sequence consisting of RGGAGRNNRAGR (R=purines; Figure 3.4). Interestingly,
motifs of transcription factors with roles in TGFβ gene expression such as SNAIL, SP1,
Yin Yang 1 (YY1), ZEB1, v-ets avian erythroblastosis virus E26 oncogene homolog 1
(ETS1), ID1, and NF-kappaB were all significantly enriched (p<0.05) within TDG
recruited sites (Table 3.1).
To identify changes in DNA methylation following a 3 hr TGFβ treatment,
MeDIP-Seq was performed using a specific 5mC antibody. Approximately 200 million
reads were sequenced which were subsequently aligned to the human genome. 75,043
DMRs in either control or treatment were identified using an FDR of 0.001 and a window
size of 200 base pairs.
A DMR was scored to the sample that had a higher methylation level (i.e. if a
region has reduced methylation after TGFβ treatment, the DMR was scored to the control
sample). Comparison of DMRs at different fold change cut-offs revealed that the control
sample had over 10 fold more DMRs than the TGFβ sample, thus confirming the global
methylation decrease observed by dot blot (Figure 3.5A). Using a 2.0 fold cut-off, 8230
DMRs were scored in the control sample. These DMRs constituted the regions that lost
methylation upon TGFβ treatment. The CDKN2B promoter exhibited a 1016 fold
decrease in methylation, and this locus again demonstrated the highest fold change
(Figure 3.5C). Importantly, the promoter of CDKN1A, which was also shown to undergo
a TGFβ-dependent decrease in methylation (Thillainadesan et al., 2012), had a 2.5 fold
decrease in methylation and provided a second positive control for the assay.
Demethylated regions in individual chromosomes was not dependent on chromosome
size, suggesting that these events were not random (Figure 3.5B). Akin to the TDG ChIPSeq, chromosome 9 has the greatest number of DMRs. Comparison of DMRs to CpG
islands revealed an overlap of 1055 DMRs with CpG islands (12.8% of DMRs, Figure
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3.5D). Analysis of known transcription factor motifs in the 8230 DMRs revealed 53
motifs that were significantly enriched in demethylated regions (Table 3.2). Many of
these were shared with TDG recruited sites, but also included uniquely enriched motifs,
such as MYC and MAX.
Based on the relationship between TDG recruitment and TGFβ dependent
demethylation at the CDKN2B promoter (Thillainadesan et al., 2012), I anticipated a
substantial overlap between TDG binding sites and DNA demethylation. Surprisingly,
comparison of the 3364 TDG binding sites with the 8230 DMRs identified only 11
overlapping genomic locations. This suggests that the overlap in TDG recruitment at
rapidly demethylated regions following TGFβ treatment is minimal in HaCaT cells.
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Figure 3.2. Experimental strategy designed to assess the role of TDG in TGFβdependent gene expression and methylation in HaCAT cells. HaCAT cells were
grown to 60% confluency, synchronized by serum starvation, and then treated with or
without TGFβ (5ng/mL) for the indicated time points.
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Figure 3.3. Genome-wide analysis of TDG recruitment in TGFβ treated HaCaT
cells. ChIP-Seq was conducted in control and TGFβ treated (90 minutes) HaCaT cells.
Peaks were determined using an FDR of 0.01 and a window size of 200 bps. A) The
number of TDG peaks that have the indicated scaled fold changes. Scaled fold change
compares the intensity of signal of the TGFβ sample to the untreated sample. B) The
number of increased TDG peaks (>2 fold) on each chromosome was plotted against
chromosome size. Labels beside each data point represent the chromosome number. C)
Representative image of TDG ChIP-Seq peaks on the CDKN2B promoter. The arrow
indicates the TSS and direction of transcription. D) Venn diagram comparing TDG
recruited sites with known CpG islands.
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Figure 3.4. De novo motifs identified in TDG recruited sites. De novo motifs were
identified in TDG recruited sites using Partek. Shown are the top 5 motifs and their
corresponding log likelihood ratio.
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Table 3.1. Enrichment of transcription factors motifs in TDG binding sites.
Increased TDG peaks were analyzed by Partek for over-representation of transcription
factor motifs found within the JASPAR database. Listed are all the enriched motifs that
contained a p-value less than 0.05.
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Figure 3.5. Genome-wide analysis of TGFβ-dependent changes in 5mC. Methylated
MeDIP-Seq was performed in control and TGFβ treated (5ng/mL for 3 hours) HaCaT
cells using a 5mC antibody. DMRs in either treated or control samples were determined
by Partek using a false discovery rate of 0.001 and a window size of 200 bps. DMRs
were scored to the sample that had the higher methylation (i.e. if methylation was lost
upon treatment, the DMR is scored in the control sample and vice versa). A) The number
of DMRs in either treatment or control that have the indicated fold changes of
methylation loss. B) The number DMRs on each chromosome was plotted against
chromosome size. Labels beside each data point represent the chromosome number. C)
Representative image of MeDIP-Seq peaks on the CDKN2B promoter. The arrow
indicates the TSS and direction of transcription. D) Venn diagram comparing DMRs with
CpG islands.
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Table 3.2. Enrichment of transcription factor motifs in TGFβ-dependent regions
with methylation loss. DMRs were analyzed for over representation of transcription
factor motifs found within the JASPAR database. Listed are all the enriched motifs that
contained a p-value less than 0.05.
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3.3

Identification of TGFβ regulated genes
In order to gain a better understanding of the relationship between TDG binding,

DNA demethylation, and TGFβ induced gene expression, RNA-Seq was conducted in
HaCaT cells treated with vehicle or TGFβ for 3h and 16h. These time points were chosen
to generate a list of genes where: (A) increased transcription would be detected early (3
hours), at a similar time point to the ChIP-Seq and MeDIP-Seq, and (B) similar genes
would continue to be upregulated at a later time point (16 hours). This is based on the
assumption that recruitment of transcriptional activators and/or removal of a repressive
mark, such as 5mC, generates a strong and persistent transcriptional response to TGFβ.
Furthermore, genes upregulated at both time points would provide a confident list of
TGFβ upregulated genes.
Normalized read counts on each gene were compared between TGFβ and control
to identify genes that were up or down regulated at each time point. Using cut-offs of 1.5
fold at both time points, 440 genes were upregulated and 387 were downregulated
(Figure 3.6A). This list included several well-studied TGFβ target genes, such as
CDKN2B, serpin peptidase inhibitor, clade E, member 1 (SERPINE1), SMAD7, ID1, and
ID2 (Figure 3.6B). Gene ontology (GO) analysis of the 440 upregulated genes indicate
several significantly enriched terms, including cell adhesion, angiogenesis, and
extracellular matrix (Figure 3.6C). Five novel TGFβ regulated genes were validated by
qPCR: SIRPA (signal-regulatory protein alpha), PDZK1 (PDZ domain containing 1), and
PIK3IP1 (phosphoinositide-3-kinase interacting protein 1) were upregulated by TGFβ,
while TDG, IFIT2 (interferon-induced protein with tetratricopeptide repeats 2), and
EREG (epiregulin) were downregulated (Figure 3.7).
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Figure 3.6. Differential RNA expression analysis of TGFβ treated HaCaT cells.
HaCaT cells were treated with TGFβ (5ng/mL) for 3 and 16 hours. RNA was collected,
converted to cDNA and subjected to high throughput sequencing. Analysis was
conducted by Partek using the RefSeq database to annotate transcripts. A) Number of
genes upregulated (top) or downregulated (bottom) and the respective fold changes for
each time point and the number of genes that are common between the time points at the
fold changes indicated. B) List of known TGFβ regulated genes and their fold changes at
each time point. C) GO analysis of genes that are upregulated 1.5 fold at both 3 and 16
hours (440 genes). To the right of each data point is the associated enrichment p-value.

45

46

Figure 3.7. Validation of novel TGFβ dependent genes. HaCaT cells were treated with
vehicle or 5ng/mL TGFβ for 3 or 16 hours. RNA was isolated, converted to cDNA, and
analyzed by SYBR green based qPCR with primers designed against the indicated
mRNA. Values shown are mean plus SD TGFβ values that are relative to the control
sample of each time point and normalized to GAPDH for three independent experiments.
Asterisks indicate the p-value (*=<0.05, **=<0.01, ***=<0.001) obtained using a paired,
two tailed t-test between treatment and control for each time point.
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3.4

Identification of TGFβ induced genes potentially regulated by TDG or loss of
methylation
The minimal overlap between TDG binding and DNA demethylation suggests

that TDG may have additional roles in TGFβ signaling, based on the time points used.
Indeed, TDG can regulate gene expression as a transcriptional coactivator independent of
its role in active demethylation (Chen et al., 2003; Tini et al., 2002; Um et al., 1998).
Thus, I decided to analyze TDG recruitment separately from demethylation while
investigating potential TGFβ target genes.
To identify potential TDG-dependent genes in TGFβ signaling, I compared TGFβ
upregulated genes identified using RNA-Seq with genome-wide TDG recruitment. I
identified 40 upregulated genes which contained at least one TDG binding site 50 kb
upstream of a TSS. To assess the distribution of TDG binding along these genes, each
gene locus was divided into regions categorized as distal (50 kb upstream to 5 kb
upstream of TSS), promoter (5 kb upstream to 3 kb downstream of TSS), 5’UTR, coding
sequence (CDS), and 3’UTR. Approximately, 52.8% of binding was found within CDS,
34.7% in the distal region, 9.7% in the promoter, and 1.4% in both the 5’UTR and 3’UTR
regions (Figure 3.8A). Top GO terms for potential TDG regulated genes include
interstitial matrix, cell adhesion, extracellular matrix organization, and cell growth
(Figure 3.8B).
To confirm this analysis, several of these genes were validated using conventional
ChIP-qPCR (Figure 3.9).

These included: (1) a distal region of the matrix

metallopeptidase 9 (MMP9) locus (-35186 bps away from TSS), (2) a previously
characterized TGFβ responsive enhancer element that controls collagen, type IV, alpha 1
(COL4A1) and COL4A2 transcription (-4652 bps away from TSS; Sumi et al., 2007), (3)
a distal region of hyaluronan synthase 2 (HAS2) (-8311 bps away from TSS), and (4) a
promoter region of adenylate kinase 8 (AK8) (+1597 bps away from TSS).
Methylation changes in the absence of TDG recruitment are potential sites of
TET-dependent oxidation of 5mC, or an alternative mechanism that removes or changes
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5mC. Regardless of the mechanism, these sites are of interest because of the role of 5mC
in regulating transcription. To identify TGFβ upregulated genes that undergo DNA
demethylation, I compared the 440 upregulated genes with the 8230 DMRs identified
using MeDIP. This analysis revealed 169 TGFβ upregulated genes that had at least one
DMR present from 50 kb upstream of a TSS to the end of the transcript. Of the DMRs
that were found in the locus of an upregulated gene, 39.8% were in the distal region,
36.1% in the CDS, 16.2% in the promoter, 5.09% in the 5’ untranslated region (UTR),
and 2.7% in the 3’UTR (Figure 3.10A).
Notably, demethylation was found on several canonical TGFβ target genes,
including: SERPINE1, growth arrest and DNA damage inducible beta (GADD45B),
transforming growth factor beta induced (TGFBI), SKI-like proto-oncogene (SKIL) and
several others (Figure 3.10B). The top GO terms in this gene list included positive
regulation of transcription from RNA polymerase II promoter, transforming growth
factor beta receptor signaling pathway, and cell motility (Figure 3.10C). For one of the
genes identified, tropomyosin 1 (TPM1), a tumour suppressor, methylation of its
promoter has been shown to prevent TGFβ-dependent upregulation in metastatic cancer
cells (Varga et al., 2005). Interestingly, 10 genes in the list have been reported to exhibit
promoter hypermethylation in at least one type of cancer (Table 3.3), and suggests that
the contribution of DNA methylation to TGFβ resistance is more widespread.
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Figure 3.8. Analysis of TDG recruitment at TGFβ upregulated genes. Binding sites
for TDG were annotated to a gene locus if the peak was located within 50 kb upstream of
the TSS to the end of the transcript. Forty TGFβ upregulated genes contained at least one
TDG binding site. A) Gene loci were divided into five distinct regions and scored for the
presence of a TDG peak: Distal (-50 kb to -5 kb from TSS), Promoter (-5 kb to +3 kb
from TSS), 5’UTR, CDS, and 3’UTR. B) GO analysis of the 40 genes potentially
regulated by TDG. Beside each data point is the associated enrichment p-value.
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Figure 3.9. Validation of TDG binding at TGFβ upregulated genes. HaCaT cells were
treated with vehicle or with 5ng/mL TGFβ for 90 minutes. ChIP analysis was performed
with a TDG-specific antibody. The DNA was analyzed using qPCR primers designed
against regions identified in the TDG ChIP-Seq experiment. IgG control values for ChIP
were subtracted from values obtained using TDG antibody. Error bars indicate standard
error of the mean (n=2).
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Figure 3.10. Analysis of TGFβ upregulated genes that exhibited methylation loss
within the locus. DMRs were annotated to a gene locus if the region was located within
50 kb upstream of the TSS to the end of the transcript. One hundred and sixty nine TGFβ
upregulated genes contained at least one DMR. A) Gene loci were divided into five
distinct regions and scored for the presence of a DMR: Distal (-50 kb to -5 kb from TSS),
Promoter (-5 kb to +3 kb from TSS), 5’UTR, CDS, and 3’UTR. B) List of previously
characterized TGFβ regulated genes that exhibited a methylation loss and the distance of
the DMR to the TSS. C) GO analysis of the 169 genes potentially regulated by
demethylation. Beside each data point is the associated enrichment p-value.
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Table 3.3. Genes with reported promoter hypermethylation in cancer that were
induced by TGFβ and had decreased methylation at or near their promoter in
HaCaTs.
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Gene

Type of cancer(s)

Reference(s)

ADRA1B

Gastric

(Noda et al., 2007)

C2CD4D

Hepatocellular Carcinoma

(Song et al., 2013c)

CYP24A1

Prostate, HCV related Hepatocellular

(Deng et al., 2010; Luo et al., 2010)

Carcinoma
FOXC2

Breast

(Lindqvist et al., 2014)

MAMDC2

Colorectal, Lung adenocarcinoma

(Mitchell et al., 2014; Selamat et al., 2012)

MSC

Lymphomas

(Ushmorov et al., 2008)

PAX1

Cervical, oral

(Huang et al., 2013; Nikolaidis et al.,
2015)

squamous cell carcinoma
PCDH8

Wilms’ tumour

(Dallosso et al., 2009)

TAGLN

Hepatocellular Carcinoma, Ovarian

(Hirasawa et al., 2006; Matsumura et al.,
2011)

UNC13A

Breast

(Legendre et al., 2015)
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3.5

Role of TDG in TGFβ growth inhibition and EMT
The recruitment of TDG to potential regulatory regions of a number of genes

suggests that it could be important for transcription changes leading to the pleiotropic
responses elicited by TGFβ stimulation. HaCaT cells have been extensively used as a
model system to study TGFβ stimulated growth inhibition and an EMT-like induction
(Gomis et al., 2006; Kortlever et al., 2008; Lamouille and Derynck, 2007; Wang et al.,
2012). To assess if TDG is required for these two TGFβ responses, I compared the
growth inhibition and EMT induction in HaCaT cells transiently transfected with siRNA
targeting TDG or a scrambled siRNA.
Prior to conducting the knockdown experiments, I analyzed TDG mRNA and
protein levels during TGFβ treatment to assess if TDG is regulated by TGFβ. RNA and
protein was collected every 24 hours from HaCaT cells treated with TGFβ or vehicle for
72 hours. TDG mRNA levels were decreased by approximately 50% in TGFβ treated
cells compared to vehicle. (Figure 3.11B). This was consistent with the RNA-Seq, where
TDG mRNA levels were decreased 1.12 fold at 3 hours and 1.76 fold at 16 hours.
Surprisingly, while mRNA levels were decreased in TGFβ treated cells compared to
control, TDG protein levels increased following TGFβ treatment and remained increased
for the duration of the experiment (Figure 3.11A and B). These results suggest that TDG
may be regulated transcriptionally and/or post-transcriptionally by TGFβ, which point to
TDG being an important player in TGFβ signaling.
Previously, it was shown that TDG knockdown in HaCaT cells prevented full
induction of CDKN2B mRNA, as assessed by qPCR (Thillainadesan et al., 2012). I was
able to confirm this result at the protein level as well (Figure 3.12). As p15 is involved in
TGFβ growth inhibition and its protein levels are reduced in siTDG cells, I reasoned that
the loss of TDG would impact the ability of cells to undergo TGFβ growth inhibition. To
assess if TDG is necessary for TGFβ growth inhibition, I performed a growth curve assay
using HaCaT cells transfected with siControl or siTDG. In unstimulated cells, both
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siControl and siTDG cells exhibited exponential growth, although siTDG cells grew
noticeably faster than siControl cells (Figure 3.12A). However, with TGFβ, both
siControl and siTDG cells had reduced growth relative to their respective vehicle
condition, suggesting that TDG knockdown did not impair TGFβ’s growth inhibition
response in HaCaT cells. TGFβ also causes growth arrest in mouse embryonic fibroblasts
(MEFs). My lab derived MEFs from Tdgflox/flox;UB-Cre/ERT2+ mice. Treatment of these
MEFs with tamoxifen activates the Cre recombinase, which excises a TDG coding
sequence preventing protein production. To test the requirement for TDG in TGFβ
induced growth arrest in MEFs, a growth curve assay was conducted in tamoxifen pretreated and untreated Tdgflox/flox;UB-Cre/ERT2+ MEFs treated with or without TGFβ.
Similar to what occurs in HaCaT cells, TDG depletion did not impact TGFβ induced
growth inhibition (Figure 3.12B). Interestingly, the TDG protein upregulation by TGFβ
observed in HaCaT cells also occurred in the control MEFs (Figure 3.12B).
The ChIP-Seq analysis indicated that TDG is recruited to genes implicated in cell
adhesion and extracellular matrix organization. Furthermore, transcription factor binding
motifs involved in EMT are enriched in TDG recruited sites. Therefore, I examined the
potential role of TDG in EMT induction. A TGFβ dependent EMT response in HaCaT
cells was observed as a morphological change in the cells from a cuboidal shape with
tight contact to an elongated shape with cell spreading. In addition, downregulation of ECadherin and upregulation of N-Cadherin confirmed the EMT response (Figure 3.13A).

I observed that TDG reduction alone resulted in a morphology change such that the cells
become more spindle shaped and were more spread out (Figure 3.13B, left). Assessing
the levels of the epithelial marker, E-Cadherin, revealed that it was slightly decreased in
siTDG cells compared to siControl, while no change was observed with the mesenchymal
marker N-Cadherin (Figure 3.13B, right). The significance behind these changes is
currently unclear, although it may indicate that TDG is necessary for maintaining the
normal epithelial status of HaCaT cells. Next, siControl and siTDG were treated with
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TGFβ to see if the reduction in TDG impacts EMT induction in HaCaT cells. Despite the
change in morphology of siTDG cells, no major difference was observed in EMT
induction after a 48 hour TGFβ treatment between siControl and siTDG HaCaT cells
(Figure 3.13C).
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Figure 3.11. TDG is regulated transcriptionally and post-transcriptionally by TGFβ.
HaCaT cells were treated with vehicle or 5ng/mL TGFβ for 72 hours. Protein and RNA
was isolated at the time of treatment (time 0) and every 24 hours after treatment. A)
Immunoblot of the protein samples probed with the indicated antibodies. The
immunoblot shown is representative of three independent experiments. B) Protein: TDG
bands were quantified and normalized to vinculin. RNA: RNA was isolated, converted to
cDNA, and analyzed by SYBR green qPCR with primers against TDG mRNA and
normalized with GAPDH primers. For each time point, the TGFβ value is relative to the
vehicle. Shown are means +SD of at least three independent experiments. Asterisks
indicate the p-value (*=<0.05, **=<0.01, ***=<0.001) obtained using a paired, two tailed
t-test between treatment and control for each time point.
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Figure 3.12. Depletion of TDG prevents p15 expression but does not impair TGFβ
induced growth inhibition in HaCaTs or MEFs. A) 72 hours post TDG knockdown by
siRNA, HaCAT cells were plated at equal density and treated with vehicle or TGFβ for
72 hours. Left, Representative immunoblot analysis of protein extracted at the 24 hour
time point. Right, Cell number was counted every 24 hours to generate a growth curve
(n=2). B) Tdgflox/flox;UB-Cre/ERT2+ MEFs were treated with or without tamoxifen to
activate Cre recombinase leading to Tdg excision. Following tamoxifen treatment, MEFs
were seeded and treated with or without TGFβ for 72 hours. Left, Representative
immunoblot analysis of protein extracted at the 48 hour time point. Right, Cell number
was counted every 24 hours to generate a growth curve (n=1).
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Figure 3.13. siRNA knockdown of TDG in HaCaT cells does not impact EMT
induction by TGFβ. A) EMT induction by TGFβ in HaCaT cells. Protein was harvested
from HaCaT cells treated with vehicle or TGFβ for 72 hours and immunoblotted with the
indicated antibodies. B) TDG knockdown changes the epithelial status of HaCaT cells. 72
hours post knockdown, an image of the cells was taken using a phase contrast microscope
and protein was harvested and immunoblotted with the indicated antibodies. C) HaCaT
cells in (B) were treated with vehicle or TGFβ for 48 hours. Protein was harvested and
immunoblotted with the indicated antibodies.
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4

Discussion

4.1

Overview
The response to TGFβ involves a complex signaling and gene regulatory network

of transcription factors, coregulators, and chromatin modifiers that regulate hundreds of
genes in a cell-type specific manner (Massagué, 2012). While work on the pathway has
focused primarily on epigenetic changes involving histone modifications, a complete
understanding of the dynamics of DNA methylation in this pathway has not been
addressed. Recent studies by our lab have demonstrated a rapid loss of DNA methylation
at the CDKN2B and CDKN1A promoters in response to TGFβ (Thillainadesan et al.,
2012). Interestingly, TGFβ stimulated recruitment of TDG to the CDKN2B promoter and
knockdown of TDG impaired DNA demethylation. These findings suggested that TDG
has a crucial role in active demethylation. Using genome-wide approaches, I have
attempted to characterize the relationship between TGFβ induced DNA demethylation
and changes in gene expression in HaCaT cells.
4.2

Global approach to identify locations of TDG recruitment and methylation
loss
To extend the studies using the CDKN2B gene locus, ChIP-Seq, using a TDG

specific antibody, and MeDIP-Seq were used to identify additional locations of TGFβdependent TDG recruitment and methylation loss, respectively. My analysis identified
several interesting correlations with respect to TGFβ-dependent TDG recruitment and
DNA demethylation. First, chromosome 9 had over three times as many TDG recruitment
sites as any other chromosome, which suggests that factors responsible for TDG
recruitment are enriched on chromosome 9. Also, there was some overlap ( ̴ 1000 sites,
12.8% of DMRs) between methylation loss and CpG islands, whereas TDG binding at
CpG islands was minimal (18 sites, 0.54% of TDG binding). CpG islands in somatic cells
are typically devoid of methylation, so it is not surprising that a high percentage of TDG
binding and DMRs occur away from CpG islands.
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Another interesting result is that numerous transcription factor motifs were
enriched within TDG binding sites and DMRs. This result suggests that TGFβ-dependent
TDG binding and demethylation occur frequently at transcriptional regulatory elements.
Of interest, SP1 was very significantly enriched in both datasets. This transcription factor
has a GC-rich consensus sequence of GGGCGG and methylation of CG in the binding
site interferes with DNA binding on some promoters (Clark et al., 1997; Douet et al.,
2007; Mulero-Navarro et al., 2006; Tian et al., 2015). This is also the case for YY1,
which has a CG in its putative motif and was significantly enriched in both datasets (Kim
et al., 2003; Sekimata et al., 2011). The enrichment of Spi-1 proto-oncogene (SPI1, also
known as PU.1) in both datasets is also interesting. This transcription factor has been
shown to interact with TET2 and DNMT3B, and the SPI1 motif was enriched in genomic
regions undergoing methylation changes during monocyte-to-osteoclast differentiation
(de la Rica et al., 2013). These discoveries support further investigation into potential
relationships between SP1, YY1, and SPI1 with DNA demethylation processes in TGFβ
signaling.
4.3

Minimal overlap between TDG recruitment and DMRs
A major goal of this study was to identify the genome-wide overlap between TDG

binding and DNA demethylation, as this would reveal other targets of TDG mediated
DNA demethylation. It is unlikely that the 11 identified genomic locations where TDG
recruitment and demethylation overlap in this study would account for the global
requirement for TDG observed by dot blot in Thillainadesan et al. One possibility for this
is that the ChIP-Seq is performed at one time point, and can only provide a ‘snapshot’ of
TDG binding. TDG binding may be very dynamic and could require multiple time points
to get a true characterization of its recruitment. Also, the resolving power of MeDIP-Seq
is lower than bisulphite sequencing, and any methylation change at a single CpG in a
heavily methylated region may not be scored as methylation loss. A final limitation of the
study is the possibility that TDG mediated DNA demethylation occurs in repetitive
elements. During data analysis of the ChIP-Seq and MeDIP-Seq screens, reads that
ambiguously align, such as repetitive elements, are discarded. As 5mC, 5fC, and 5caC are
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enriched at major satellite repeats in mESCs (Shen et al., 2013), methylation changes and
TDG recruitment could be occurring at these repetitive elements that went unaccounted
for in this study.
Additional factors with potential roles in DNA demethylation may also be
responsible for the global DNA methylation changes. The dot blot analysis showed a
TGFβ-dependent decrease in 5mC and 5hmC and an increase in 5fC. The AID/APOBEC
mechanism could be responsible for reduced levels of 5mC and 5hmC by TGFβ by
converting these modifications to thymine and 5hmU, respectively. Also, increased TET
activity could explain the increased 5fC and decreased 5mC/5hmC. Increased TET
activity would convert 5mC and 5hmC to 5fC or 5caC. Furthermore, there was evidence
of both of these processes on the CDKN2B promoter (Thillainadesan et al., 2012). To test
these possibilities, knocking down TET proteins and AID/APOBEC in HaCaT cells and
treating with TGFβ followed by dot blot analysis of the metabolites would be
informative. If positive, ChIP-Seq could be performed with antibodies against these
proteins to see if their binding overlaps with methylation changes.
4.4

Potential TDG-dependent TGFβ regulated genes
Long before its role in DNA demethylation was realized, TDG was found to

function as a transcriptional coactivator (Cortázar et al., 2011; Xu et al., 2015). Thus,
TDG may fulfill an important transcriptional coregulator function in TGFβ signaling.
Comparison of binding with TGFβ upregulated genes revealed 40 potential genes that
TDG may regulate during TGFβ signaling. The majority of TDG binding occurred
several kb away from the TSS, raising the possibility that TDG is recruited to distal
regulatory elements. For example, TDG recruitment occurred at a previously identified
TGFβ responsive enhancer that controls COL4A2 transcription (Sumi et al., 2007).
Through its association with numerous transcription factors, particularly CBP, TDG
recruitment could have an important function in the activation of these putative enhancer
elements. Furthermore, there are multiple studies demonstrating that active DNA
demethylation involving TDG occurs at some enhancers (Cortellino et al., 2011; Raiber
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et al., 2012; Song et al., 2013b). Unfortunately, TGFβ enhancer elements in HaCaT cells
have not been characterized, preventing a thorough understanding of TDG recruitment at
these sites.
4.5

Potential TGFβ target genes regulated by DNA demethylation
Active demethylation has been documented for several signaling pathways such

as estrogen (Métivier et al., 2008), retinoic acid (Le May et al., 2010), T cell activation
(Bruniquel and Schwartz, 2003), glucocorticoid (Wiench et al., 2011), and TGFβ
(Thillainadesan et al., 2012). In this study, I have identified 169 candidate genes where
DNA demethylation may contribute to the regulation of those genes by TGFβ, suggesting
that DNA demethylation is involved in transcriptional induction of a subset of genes.
Strikingly, these DNA demethylation changes occurred at several canonical TGFβ target
genes, including SERPINE1, GADD45B, TGFBI, SKIL, and MMP9. However, for the
majority of genes demethylation was found several kilobases away from the TSS.
Interestingly, active DNA demethylation at enhancer elements is common (Song and He,
2013), and DNA methylation levels at enhancers is often a better indication of expression
levels than promoter methylation (Aran and Hellman, 2013). Therefore, the methylation
changes observed in this study could represent important regulatory events in TGFβ
signaling. It would be interesting to test the requirement of the TET proteins and
AID/APOBEC in growth inhibition and EMT in response to TGFβ, as these are likely
candidates involved in initiating the methylation changes.
Ten genes, including TPM1, exhibited a TGFβ-dependent methylation loss in
their respective promoters. These genes have also been found hypermethylated in some
cancers. TPM1 is a tumour suppressor gene that is induced by TGFβ only in metastatic
cancer cells when its promoter is unmethylated (Varga et al., 2005). If methylation
prevents TGFβ induction in cancer cells for the other genes identified, this may
demonstrate a common feature in cancer cells that alters their responsiveness to TGFβ.
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4.6

TGFβ regulation of TDG mRNA and protein levels
I observed that TDG protein levels increased while its mRNA decreased in

response to TGFβ, suggesting that TDG appears to be regulated at multiple levels. TDG
transcription is directly upregulated by c-MYC in MCF10 cells (Bott et al., 2015). Thus,
downregulation of c-MYC by TGFβ may account for the decreased TDG mRNA levels.
Additionally, YY1, lymphoid enhancer-binding factor 1 (LEF1), cAMP responsive
element binding protein (CREB), and signal transducer and activator of transcription 1
(STAT1) transcription factor motifs are on the TDG promoter and may also mediate
downregulation of TDG mRNA by TGFβ.
In contrast to mRNA levels, a surprising result was the increase of TDG protein in
TGFβ treated cells compared to control. The most likely explanation for this result is
post-translational mechanisms that regulate TDG protein stability. TDG is known to be
regulated by post-translational modifications, including phosphorylation, acetylation, and
sumoylation (Hardeland et al., 2002; Madabushi et al., 2013; Mohan et al., 2009).
However, these studies have not shown an impact of these modifications on stability or
expression of TDG protein. TDG levels are also regulated in a cell-cycle dependent
manner. TDG is rapidly degraded in cells entering S phase by a mechanism that involves
the ubiquitin proteasome system, while all other stages of the cell cycle express high
amounts of TDG (Hardeland et al., 2007). Thus, an increase in TDG levels may be a
consequence of G1/S phase arrest induced by TGFβ, which would result in an
accumulation of TDG protein.
4.7

Role of TDG in TGFβ growth inhibition and EMT induction
In HaCaT cells, TGFβ causes a strong growth inhibition primarily through

upregulation of cyclin dependent inhibitors and repression of MYC and ID1/2 (Pardali
and Moustakas, 2007). Previous work (Thillainadesan et al., 2012) and the results
presented in this study, have shown that TDG is critical for the induction of CDKN2B by
TGFβ. Despite this, loss of TDG was not sufficient to prevent TGFβ growth inhibition.
This may be attributed to functional redundancies, as TGFβ can still induce growth
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inhibition in cells lacking CDKN2B (Latres et al., 2000). I also investigated the role of
TDG in EMT induction in HaCaT cells. Although the legitimacy of EMT in HaCaT cells
is controversial (Brown et al., 2004), the cells did exhibit an EMT-like response with
TGFβ treatment. I initially predicted that loss of TDG would impair TGFβ induced EMT,
since TDG recruitment was enriched with SNAIL and ZEB1 motifs and was found at
genes involved in cell adhesion. However, I found that TDG depletion did not prevent
TGFβ induced EMT in HaCaT cells. Many transcription factors are responsible for the
transcriptional changes leading to TGFβ growth inhibition and EMT, thus, the loss of just
TDG is likely not enough to impair the robustness of this response in HaCaT cells.
Additional experiments are needed to completely understand the role of TDG in
TGFβ signaling. Overexpressing TDG in cancer cells that are TGFβ insensitive would be
an informative to assess changes in responsiveness to TGFβ. Finally, assessing the role of
TDG in TGFβ’s regulation of ESC pluripotency would also be worthwhile given the role
of TDG in embryogenesis and reprogramming (Cortázar et al., 2011; Hu et al., 2014), the
finding that 5fC/5caC accumulate at active enhancers in ESCs in the absence of TDG
(Shen et al., 2013; Song et al., 2013b), and the importance of enhancers in interpreting
TGFβ signals in ESC differentiation (Beyer et al., 2013; Xi et al., 2011).
4.8

Summary & future directions
The major goal of this thesis was to assess how TDG mediated active

demethylation affects TGFβ genome-wide. TDG ChIP-Seq and MeDIP-Seq experiments
before and after TGFβ treatment in HaCaT cells revealed only 11 genomic locations
where TDG recruitment overlaps with a methylation loss. Due to several limitations of
the ChIP-Seq and MeDIP-Seq experiments, it is likely that this overlap is an
underestimate of true TGFβ-dependent TDG DNA demethylation events. Other
mechanisms involved in DNA demethylation, such as TET proteins and AID, may also
be involved in global DNA demethylation by TGFβ. This is supported by the TGFβdependent decrease in 5mC and 5hmC and increase in 5fC observed by dot blot.
Clarification of these possibilities is an avenue for future work.
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Comparison of the TGFβ upregulated genes to the ChIP-Seq and MeDIP-Seq
screens revealed 40 potential TDG regulated genes and 169 genes potentially regulated
by demethylation. Also, numerous transcription factor motifs were enriched at TDG
binding sites and regions undergoing demethylation. Collectively, these results suggest
that TDG and DNA demethylation could have important functions at transcriptional
regulatory elements (e.g. enhancers) to regulate transcription of TGFβ target genes.
Exploring the role of DNA methylation and TDG in controlling cell-type specific
responses to TGFβ requires further investigation but could provide valuable insight into
how TGFβ signals are interpreted in developmental and disease processes.
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